548 related articles for article (PubMed ID: 26920382)
1. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry.
Thiel S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
Mult Scler; 2016 May; 22(6):801-9. PubMed ID: 26920382
[TBL] [Abstract][Full Text] [Related]
2. Glatiramer acetate during early pregnancy: A prospective cohort study.
Herbstritt S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
Mult Scler; 2016 May; 22(6):810-6. PubMed ID: 26754804
[TBL] [Abstract][Full Text] [Related]
3. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry.
Hellwig K; Geissbuehler Y; Sabidó M; Popescu C; Adamo A; Klinger J; Ornoy A; Huppke P;
J Neurol; 2020 Jun; 267(6):1715-1723. PubMed ID: 32100126
[TBL] [Abstract][Full Text] [Related]
4. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort.
Boskovic R; Wide R; Wolpin J; Bauer DJ; Koren G
Neurology; 2005 Sep; 65(6):807-11. PubMed ID: 16186517
[TBL] [Abstract][Full Text] [Related]
5. The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis.
Burkill S; Vattulainen P; Geissbuehler Y; Sabido Espin M; Popescu C; Suzart-Woischnik K; Hillert J; Artama M; Verkkoniemi-Ahola A; Myhr KM; Cnattingius S; Korhonen P; Montgomery S; Bahmanyar S
PLoS One; 2019; 14(12):e0227120. PubMed ID: 31887199
[TBL] [Abstract][Full Text] [Related]
6. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis.
Sandberg-Wollheim M; Frank D; Goodwin TM; Giesser B; Lopez-Bresnahan M; Stam-Moraga M; Chang P; Francis GS
Neurology; 2005 Sep; 65(6):802-6. PubMed ID: 16093457
[TBL] [Abstract][Full Text] [Related]
7. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis.
MacDonald SC; McElrath TF; Hernández-Díaz S
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):556-560. PubMed ID: 30834654
[TBL] [Abstract][Full Text] [Related]
8. Interferon beta babies.
Waubant E; Sadovnick AD
Neurology; 2005 Sep; 65(6):788-9. PubMed ID: 16186513
[No Abstract] [Full Text] [Related]
9. Interferon beta, birth weight and pregnancy in multiple sclerosis.
Hellwig K; Agne H; Gold R
J Neurol; 2009 May; 256(5):830-1. PubMed ID: 19240959
[No Abstract] [Full Text] [Related]
10. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.
Lu E; Wang BW; Guimond C; Synnes A; Sadovnick D; Tremlett H
Neurology; 2012 Sep; 79(11):1130-5. PubMed ID: 22933738
[TBL] [Abstract][Full Text] [Related]
11. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes.
Djulus J; Koren G; Einarson TR; Wilton L; Shakir S; Diav-Citrin O; Kennedy D; Voyer Lavigne S; De Santis M; Einarson A
J Clin Psychiatry; 2006 Aug; 67(8):1280-4. PubMed ID: 16965209
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
Portaccio E; Annovazzi P; Ghezzi A; Zaffaroni M; Moiola L; Martinelli V; Lanzillo R; Brescia Morra V; Rinaldi F; Gallo P; Tortorella C; Paolicelli D; Pozzilli C; De Giglio L; Cavalla P; Cocco E; Marrosu MG; Patti F; Solaro C; Bellantonio P; Uccelli A; Laroni A; Pastò L; Giannini M; Trojano M; Comi G; Amato MP;
Neurology; 2018 Mar; 90(10):e823-e831. PubMed ID: 29438046
[TBL] [Abstract][Full Text] [Related]
13. [Disease modifying drugs in multiple sclerosis and pregnancy].
Tur C; Tintoré M; Aguilera C
Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
[No Abstract] [Full Text] [Related]
14. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study.
Weber-Schoendorfer C; Schaefer C
Mult Scler; 2009 Sep; 15(9):1037-42. PubMed ID: 19692433
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study.
Weber-Schoendorfer C; Oppermann M; Wacker E; Bernard N; ; Beghin D; Cuppers-Maarschalkerweerd B; Richardson JL; Rothuizen LE; Pistelli A; Malm H; Eleftheriou G; Kennedy D; Kadioglu Duman M; Meister R; Schaefer C
Br J Clin Pharmacol; 2015 Oct; 80(4):727-39. PubMed ID: 25808588
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis.
Amato MP; Portaccio E; Ghezzi A; Hakiki B; Zipoli V; Martinelli V; Moiola L; Patti F; La Mantia L; Mancardi GL; Solaro C; Tola MR; Pozzilli C; De Giglio L; Totaro R; Lugaresi A; Di Tommaso V; Paolicelli D; Marrosu MG; Comi G; Pellegrini F; Trojano M;
Neurology; 2010 Nov; 75(20):1794-802. PubMed ID: 21079181
[TBL] [Abstract][Full Text] [Related]
17. Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?
Patti F; Cavallaro T; Lo Fermo S; Nicoletti A; Cimino V; Vecchio R; Laisa P; Zarbo R; Zappia M
J Neurol; 2008 Aug; 255(8):1250-3. PubMed ID: 18677640
[TBL] [Abstract][Full Text] [Related]
18. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes.
Bérard A; Zhao JP; Shui I; Colilla S
Ann Rheum Dis; 2018 Apr; 77(4):500-509. PubMed ID: 29222350
[TBL] [Abstract][Full Text] [Related]
19. The safety of cetirizine during pregnancy. A prospective observational cohort study.
Weber-Schoendorfer C; Schaefer C
Reprod Toxicol; 2008 Sep; 26(1):19-23. PubMed ID: 18571373
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study.
McKenna K; Koren G; Tetelbaum M; Wilton L; Shakir S; Diav-Citrin O; Levinson A; Zipursky RB; Einarson A
J Clin Psychiatry; 2005 Apr; 66(4):444-9; quiz 546. PubMed ID: 15816786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
